Sign in
Enrolling by invitationNo phase

Boomerang Catheter for Chronic Limb-Threatening Ischemia With No Other Treatment Options

Tests a catheter procedure for adults with severe leg artery blockage and no other options.

Key facts

Who runs it
Aveera Medical, Inc.
Where
Bethlehem, Boston, Chattanooga, Chicago, Dallas, Galloway, Houma, Houston, Jacksonville, Lake Success, Lebanon, Murphy, Nashville, New York, Philadelphia, San Bernardino, Seattle, Spartanburg, Sylmar, Tigard, Torrance, West Orange, Whittier, and Wilmington, United StatesSee the 25 sites
Trial code
Registry title
Pivotal Trial of the Boomerang Catheter for pDVA
Status
Enrolling by invitation
People taking part
120 people, planned
Started
16 Apr 2024
Expected to end
31 Mar 2030
Type of study
Interventional
Treatments tested
  • Boomerang Catheter
Record updated
24 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with severe chronic limb-threatening ischemia (very poor blood flow to the leg) who have no other option to save the limb. They will be treated with the Boomerang Catheter.

Age
18 years and older
Sex
All sexes
Disease stage
Rutherford Category 5 or 6 chronic limb-threatening ischemia, with tests showing very low blood flow in the leg (e.g., ABI ≤ 0.39, TP / TcPO2 < 30 mm Hg). Doctors and a review committee must agree no bypass, surgery or catheter treatment is possible. The main wound must be stable.
Earlier treatment
Earlier stents in the inflow leg arteries are allowed. People cannot join if they had a leg artery bypass on the same leg within 30 days, or a major amputation of that leg.
Biomarker or test result
Imaging must show an open inflow artery (< 50% narrowing). Ultrasound must show the target vein is clot-free and at least 2.0mm wide. Women who could get pregnant need a negative urine pregnancy test within 7 days before the procedure.

Main reasons for not taking part

  • Expected to live less than 12 months
  • On dialysis, or serious kidney disease with serum creatinine > 2.5 mg/dl (221 µmol/L)
  • Other leg blood vessel diseases such as vasculitis, Buerger's disease or a clot in the target vein
  • Stroke in the past 3 months with Rankin score of ≥ 2, or NYHA Class IV heart failure
  • Cannot take aspirin, clopidogrel-type drugs or blood thinners, or allergy to the device materials

The registry criteria, word for word

Show all 25 criteriaShow less

Who can take part

  • Patient is age ≥ 18 years
  • Patient has confirmed clinical diagnosis of Rutherford Category (RC) 5 or 6 Chronic Limb-Threatening Ischemia (CLTI) with previous angiogram or hemodynamic evidence (e.g., ABI ≤ 0.39, TP / TcPO2 < 30 mm Hg) demonstrating severely diminished arterial perfusion of the index limb
  • Assessment by the PI and an Independent Review Committee (IRC) determines that patient has no option for conventional distal bypass, surgical or endovascular therapy for limb salvage
  • Inflow artery criteria:; Imaging confirmation of patent inflow artery (< 50% stenosis) from Aortic bifurcation to tibial trifurcation
  • Target conduit vein criteria:; Duplex ultrasound confirms that vein is free from thrombus, contiguous from the intended anastomosis site through the lateral plantar vein, and ≥ 2.0mm lumen-lumen diameter (with tourniquet applied) throughout
  • Patient may be scheduled for a planned minor amputation (toe, ray, or trans-metatarsal) within 30 days after index procedure
  • Prior stent(s) to inflow arteries (i.e., Iliac, SFA, Popliteal) are allowed
  • Patient is willing and able to provide written informed consent
  • Patient meets institutional criteria for procedure clearance and is able to comply with study requirements per PI judgement
  • Diabetic patients have adequate glycemic control per investigator judgement
  • Female patients of childbearing potential have a negative pregnancy test within 7 days prior to index procedure (urine)
  • Patient is enrolled in a wound care network and has an adequate support network to ensure compliance with medication regimen and follow-up study visits
  • PI determines that the primary wound is stable (e.g., not rapidly deteriorating or showing signs of healing)

Who cannot take part

  • Prior peripheral arterial bypass procedure on index limb within 30 days
  • Previous major amputation of the target limb or absence of adequate viable tissue for below-ankle (e.g., mid-foot) amputation
  • The patient is currently participating in another investigational drug or device study that has not completed the primary endpoint and that clinically interferes with the endpoints of this study per PI judgement
  • Patient cannot be adequately treated with study medications due to known contraindication to aspirin, ADP antagonists such clopidogrel, prasugrel or ticagrelor, or anticoagulants such as heparin or bivalirudin
  • Patient has had a stroke within the previous 3 months with residual Rankin score of ≥ 2
  • Patient has a lower extremity vascular disease that may inhibit the procedure and/or jeopardize wound healing (e.g., vasculitis, Buerger's disease, significant edema in the target limb, deep venous thrombus in the target vein, hyperpigmentation, or medial ulceration above the ankle)
  • Patient has known hypersensitivity or contraindication to materials used during the procedure (cobalt, chromium, nickel, platinum, tungsten, acrylic and fluoro polymers) or a known contrast sensitivity that cannot be adequately pre-medicated
  • NYHA Class IV heart failure which may compromise patient's ability to safely undergo a percutaneous procedure, per PI judgment
  • Significant acute or chronic kidney disease with a serum creatinine of > 2.5 mg/dl in patients not undergoing dialysis
  • Life expectancy < 12 months
  • Patient is dialysis dependent
  • Patient is non-ambulatory due to above-ankle amputation of contralateral limb

Where in United States

  • St. Luke's University HospitalBethlehem, United StatesEnrolling by invitation
  • Massachusetts General HospitalBoston, United StatesEnrolling by invitation
  • VIC Vascular InstituteChattanooga, United StatesEnrolling by invitation
  • Rush University Medical CenterChicago, United StatesEnrolling by invitation
  • UT Southwestern Medical CenterDallas, United StatesEnrolling by invitation
  • Vascular Institute at AMIGalloway, United StatesEnrolling by invitation
  • Cardiovascular Institute of the SouthHouma, United StatesEnrolling by invitation
  • Baylor College of MedicineHouston, United StatesEnrolling by invitation
  • HOPE Vascular and PodiatryHouston, United StatesEnrolling by invitation
  • First Coast Cardiovascular InstituteJacksonville, United StatesEnrolling by invitation
  • Northwell Health - Lake SuccessLake Success, United StatesEnrolling by invitation
  • Dartmouth Hitchcock Medical CenterLebanon, United StatesEnrolling by invitation
  • Sunrise VascularMurphy, United StatesEnrolling by invitation
  • Vanderbilt University Medical CenterNashville, United StatesEnrolling by invitation
  • Weill Cornell Medical CenterNew York, United StatesEnrolling by invitation
  • Penn MedicinePhiladelphia, United StatesEnrolling by invitation
  • Arrowhead Regional Medical CenterSan Bernardino, United StatesEnrolling by invitation
  • University of Washington MedicineSeattle, United StatesEnrolling by invitation
  • Spartanburg Regional Medical CenterSpartanburg, United StatesEnrolling by invitation
  • Olive View-UCLA Medical CenterSylmar, United StatesEnrolling by invitation
  • Advanced Vascular CentersTigard, United StatesEnrolling by invitation
  • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical CenterTorrance, United StatesEnrolling by invitation
  • American Endovascular and Amputation PreventionWest Orange, United StatesEnrolling by invitation
  • PIH Whittier HospitalWhittier, United StatesEnrolling by invitation
  • Endovascular ConsultantsWilmington, United StatesEnrolling by invitation

About the trial

What the trial wants to find out

The purpose of this study is to establish the safety and effectiveness of the Boomerang Catheter for percutaneous Deep Venous Arterialization (pDVA) to treat no-option Chronic Limb-Threatening Ischemia.

The group in the trial

  • Treated with Boomerang CatheterTreatment being tested

    Treatment: Boomerang Catheter

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Pivotal Multicenter Trial of the Boomerang® Catheter for Percutaneous Deep Vein Arterialization (pDVA)
Plain-language title
Boomerang Catheter for Chronic Limb-Threatening Ischemia With No Other Treatment OptionsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
24 July 2026